About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
Sep 10, 2020...
A novel treatment for Alzheimer’s, developed by one of Israel’s top scientists, is preparing to launch a Phase 1 clinical trial and, if successful, it could change the course of the disease and arrest its progression.
The therapy, developed by ImmunoBrain Checkpoint and based on 20 years of work by Prof. Michal Schwartz of the Weizmann Institute of Science demonstrating that the immune system is needed for the maintenance of healthy brain function and repair, would contribute to the understanding of the biology of Alzheimer’s disease.
May 14, 2021... The American Committee’s Women for Science (W4S) initiative hosted an engaging webinar, featuring two leading neuroscientists: Weizmann Institute President Prof. Alon Chen and Prof. Michal Schwartz of the Department of Neurobiology. Following introductory remarks by W4S Co-Chair Ellen Merlo, Prof. Chen provided an overview Weizmann’s flagship Institute for Brian and Neural Sciences. Featured speaker Prof. Michal Schwartz then presented her trailblazing research, based on her groundbreaking discoveries about the connection between the immune system and the brain. Her innovative work is paving the way to a revolutionary platform for the treatment of Alzheimer’s and age-related dementia. To conclude the program, Prof. Schwartz participated in a dynamic Q&A, moderated by Ellen Merlo.
https://www.weizmann-usa.org/news-media/feature-stories/june-is-alzheimer-s-brain-awareness-month/
Jun 07, 2021...
Despite decades of research, we don’t know much about the brain. It is as strange as the deep sea, as complex as a computer, as mysterious as the universe – and it makes us who we are, as humans and individuals.
Understanding this most complex of organs is more important now than ever: lifespans are increasing and, thus, so are age-related conditions such as Alzheimer’s and Parkinson’s; awareness of mental illness is rising, as is the need for effective treatments; rates of autism are still going up. Fortunately, technological advances over the past several years are, for the first time, allowing scientists to study the brain at a level of detail never before possible.
Aug 27, 2021... ImmunoBrain Checkpoint Inc. (“IBC”) an innovative biopharmaceutical company developing potential disease-modifying immune therapies that harness the power of the immune system to help protect and repair the brain to combat neurodegenerative diseases, announced today that the National Institute on Aging (NIA) of the US National Institutes of Health (NIH) has awarded the Company a grant totaling $5 million over three years to support a first-in-human clinical study of IBC-Ab002, for the treatment of Alzheimer’s disease.
©2023 American Committee for the Weizmann Institute of Science
FOR THE FOURTH CONSECUTIVE YEAR
